Table 4.

Genetic features of pancreatic neuroendocrine neoplasms

Case no. in Tables 1 and 2	KRAS sequencing	TP53		RB1		CDKN2A/p16
		TP53 sequencing	p53 IHC	RB1 sequencing	Rb IHC	CDKN2A/p16 sequencing	p16 IHC
Small cell neuroendocrine carcinoma (Small cell NEC)
2	WT	Nonsense Mutation (p.E307X)	abnormal	Frameshift Mutation (c.803_804del)	negative	WT	positive
3	WT	WT	abnormal	Splice Site Mutation (c.861-2T>A)	negative	WT	positive
4	WT	WT	abnormal	WT	negative	WT	negative
5	Missense Mutation (p.G12L)	Missense Mutation (p.S127T)	abnormal	Splice Site Mutation (c.1219-2A>G)	negative	WT	positive
Large cell neuroendocrine carcinoma (Large cell NEC)
10	Missense Mutation (p.G12D)	Nonsense Mutation (p.R196X)	abnormal	Frameshift Mutation (c.2237_2251del)	negative	WT	positive
11	WT	Missense Mutation (p.V216L)	abnormal	Frameshift Mutation (c.868_869insA)	negative	WT	positive
12	WT	WT	abnormal	WT	negative	WT	negative
Well-differentiated neuroendocrine tumor (NET, G2, intermediate-grade)
20	WT	WT	normal	WT	positive	WT	positive
21	WT	WT	normal	WT	positive	WT	positive
22	WT	WT	normal	WT	positive	WT	positive
23	WT	WT	normal	WT	positive	WT	positive
24	WT	WT	normal	WT	positive	WT	positive
Well-differentiated neuroendocrine tumor (NET, G1, low-grade)
25	WT	WT	normal	WT	positive	WT	positive
26	WT	WT	normal	WT	positive	WT	positive
27	WT	WT	normal	WT	positive	WT	positive
28	WT	WT	normal	WT	positive	WT	positive
29	WT	WT	normal	WT	positive	WT	positive
30	WT	WT	normal	WT	positive	WT	positive

IHC, immunohistochemistry; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; WT, wild-type gene.